• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

    10/7/21 9:00:00 AM ET
    $FGEN
    $ITCI
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email

    Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.

    "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this management shift is an important step in scaling Cibus to address the enormous opportunities that exist in the global agriculture solutions market."

    "Cibus' Rapid Trait Development System™ technology is set to play a leading role in the global drive to make farming more efficient and sustainable. The tremendous technological breakthroughs in gene editing by our scientists and others, have placed agriculture at a major point of inflection in the use of environmentally sound biological solutions to address both farming sustainability and agriculture's impact on climate change," said Mr. Riggs.

    "Cibus' focus is productivity improvements in the major row crops: canola, rice, soybean, wheat, and corn. These crops are grown annually on billions of acres of land. Addressing the use of chemicals and the impact of climate change on these major global crops is critical to achieving virtually every sustainable development and climate goal. I am excited to work more closely with the team at Cibus in this enormous opportunity to make Cibus a global leader in the transformation of agriculture."

    Mr. Riggs has an extensive record of executive leadership and innovation in the healthcare and biotechnology fields. He is a co-founder, former Chairman and director of Royalty Pharma (NASDAQ:RPRX), the largest acquirer of pharmaceutical royalties and leading funder of innovation in the life sciences. In addition, he has co-founded and served on the board of several important biotechnology companies including Sugen (NASDAQ:SUGN) and Fibrogen (NASDAQ:FGEN).

    Previously, Mr. Riggs served as President and director of Biomatrix, Inc. (NYSE:BXM) from 1996 until its sale to Sanofi/Genzyme. During his tenure, he led the development and global commercial launch of an important new category for the treatment of osteoarthritis: viscosupplementation; and the leading product in the category: Synvisc®. Mr. Riggs also served as CEO of RF&P Corp., an investment company owned by the Virginia Retirement System until its sale to Lazard. He is a Director of Intra-cellular Therapies, Inc (NASDAQ:ITCI); Stage Zero Life Sciences (OTC:SZLSF), and a co-founder and Partner of Scientia Ventures LLC, a leading venture investor in Cibus. He was formerly a Managing Director at PaineWebber, Inc.

    Mr. Riggs is also a pioneer in the field of Systems Economics and the inventor of a new information system called FIS® (Functional Information System) for the functional mapping of systems data in biology and economics. This technology is covered by several patents of which one is with Dr. Beetham and Greg Gocal, PhD, Cibus' Chief Scientific Officer. FIS is currently the basis for two investment and research analytics companies: Syntax LLC and Locus Analytics LLC.

    "The addition of Rory to our executive team is a major step in accomplishing our goal of redefining and reshaping the agricultural crop protection business," said Dr. Gocal, co-founder, Chief Scientific Officer and Executive Vice President at Cibus. "The continued technological breakthroughs in genomics and gene editing have created a generational moment in one of the most exciting scientific periods of our lifetime and we look forward to making significant contributions to improve farming through biology."

    Mr. Riggs received his BA from Middlebury College and his MBA from Columbia University's Graduate School of Business.

    About Cibus

    Cibus is a leading agricultural biotechnology company that uses precision gene editing to breed plants with new genetic traits that make them healthier and better able to thrive in their changing environments. Cibus' traits improve farming productivity by increasing crop yields and reducing inputs such as fungicides, herbicides, pesticides, and fertilizers. Cibus' trait products are important drivers of farming sustainability and the reduction of agriculture's carbon footprint. For more information, please visit www.cibus.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005383/en/

    Get the next $FGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FGEN
    $ITCI
    $RPRX

    CompanyDatePrice TargetRatingAnalyst
    Royalty Pharma plc
    $RPRX
    5/16/2025$51.00Overweight
    Morgan Stanley
    Intra-Cellular Therapies Inc.
    $ITCI
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    Intra-Cellular Therapies Inc.
    $ITCI
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    Intra-Cellular Therapies Inc.
    $ITCI
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    Royalty Pharma plc
    $RPRX
    6/3/2024$28.00Buy → Neutral
    UBS
    Intra-Cellular Therapies Inc.
    $ITCI
    1/3/2024$83.00Outperform
    Robert W. Baird
    Intra-Cellular Therapies Inc.
    $ITCI
    12/11/2023$75.00Outperform
    TD Cowen
    FibroGen Inc
    $FGEN
    8/8/2023$4.00 → $2.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $FGEN
    $ITCI
    $RPRX
    SEC Filings

    See more
    • FibroGen Inc filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - FIBROGEN INC (0000921299) (Filer)

      6/13/25 4:05:27 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - FIBROGEN INC (0000921299) (Filer)

      6/12/25 4:27:12 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - FIBROGEN INC (0000921299) (Filer)

      6/9/25 4:00:54 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Announces 1-for-25 Reverse Stock Split

      SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen's common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company's existing trading symbol "FGEN," with the new CUSIP number 31572Q881. The Reverse Stock Split was previously approved by stockholders at the Company's annual meeting of stockholders held on June 4, 2025 ("2025 Annual Meeting"), with the final ratio determined by the Company's Board of Directors. O

      6/12/25 4:02:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

      SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

      6/9/25 4:02:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Royalty Pharma with a new price target

      Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

      5/16/25 8:05:49 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies downgraded by Mizuho with a new price target

      Mizuho downgraded Intra-Cellular Therapies from Outperform to Neutral and set a new price target of $132.00 from $140.00 previously

      2/24/25 7:10:56 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Intra-Cellular Therapies from Buy to Hold and set a new price target of $132.00 from $119.00 previously

      1/31/25 7:02:57 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      7/2/25 4:33:27 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fernandez Henry A was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 65,324 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:06:05 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bassler Bonnie L was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 71,118 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:04:29 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      7/2/25 4:33:27 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/25/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/24/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

      SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

      6/9/25 4:02:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Appoints David DeLucia as Chief Financial Officer

      SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

      12/16/24 8:05:00 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

      Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that sharehold

      5/12/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    $ITCI
    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/14/24 4:52:23 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/12/24 4:01:23 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/12/24 2:33:26 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care